We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

5 hedge funds and large institutions have $540K invested in Biotech Acquisition Company Unit in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $517K → $540K (+$22.6K)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$130K

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$112K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$401K – – –
VF
2
Virtu Financial
New York
$130K +$130K +12,968 New
Morgan Stanley
3
Morgan Stanley
New York
$5.53K – – –
UBS Group
4
UBS Group
Switzerland
$2.11K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$1K – – –
CS
6
Clear Street
New York
– -$112K -11,291 Closed

BIOTU Hedge Fund Activity: Q4 2022 in Review

5 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q4 2022, worth a combined $540K — up 4.4% from $517K a quarter earlier.

Fund positioning in BIOTU was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $130K. The largest seller was Clear Street, exiting entirely with an estimated $112K sold.

  • 5 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $540K of Biotech Acquisition Company Unit stock for Q4 2022, up 4.4% quarter-over-quarter.
  • 1 fund opened new Biotech Acquisition Company Unit positions in Q4 2022 and 1 closed out, a net change of 0 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q4 2022 was Virtu Financial, an estimated $130K added.
  • The largest Biotech Acquisition Company Unit seller in Q4 2022 was Clear Street, an estimated $112K sold.

Based on aggregated 13F filings for Q4 2022.